Skip to main content

Table 7 The sensitivity analysis at 25% sharing rate for cumulative annual cost saving, cost - effectiveness and cost – benefit of SIF in Montreal

From: A cost-benefit/cost-effectiveness analysis of proposed supervised injection facilities in Montreal, Canada

Variables Annual cost of operation Sharing rate # of HIV averted # of HCV averted HIV cost saved HCV cost saved Cost-effectiveness ratio HCV Cost-effectiveness ratio HIV Cost-benefit ratio HCV Cost-benefit ratio HIV
Post SIF $2,182,800 25% 10 64 -$77,250 $66,352 $34,106 $218,280 1.03 1
Two SIF $4,365,600 20% 19 119 -$365,055 -$183,583 $36,686 $229,768 0.96 0.92
Three SIF $6,548,400 15% 23 142 -$1,705,635 -$1,558,094 $46,156 $284,713 0.76 0.74
Four SIF $8,731,200 13% 27 166 -$3,046,215 -$2,897,462 $52,598 $323,377 0.67 0.65
Five SIF $10,914,000 11% 31 190 -$4,386,795 -$4,236,830 $57,442 $352,065 0.61 0.6
Six SIF $13,096,800 9% 35 213 -$5,727,375 -$5,611,341 $61,487 $374,194 0.57 0.56
Seven SIF $15,279,600 7% 39 237 -$7,067,955 -$6,950,709 $71,735 $436,560 0.55 0.54
Average $8,731,200 14% 26 154 -$3,256,770 -$3,319,178 $56,696 $335,815 0.62 0.63